Clinical uses of gonadotropin-releasing hormone analogues
Summary
Foundational clinical review of GnRH analog applications including endometriosis, uterine leiomyoma, precocious puberty, and hormone-dependent cancers. Established that GnRH agonists first stimulate then inhibit gonadotropin secretion through pituitary receptor downregulation, with few side effects.
Key Findings
- GnRH agonists downregulate pituitary receptors, producing reversible chemical gonadectomy
- Proved efficacious for endometriosis, fibroids, precocious puberty, and hormone-dependent cancers
- Long-term use may lead to skeletal calcium loss due to hypoestrogenism
Access Full Text
Read the complete published study from the original source.
View on Publisher SiteRelated Monographs
Related Studies
View all →Gonadotropin-releasing hormone analogs: mechanisms of action and clinical applications in female reproduction
Wu HM, Chang HM, Leung PCK
Frontiers in Neuroendocrinology
Comprehensive review of GnRH signaling in reproductive biology. Documented extra-hypothalamic GnRH receptors in ovary, endometrium, and myometrium. Discussed new developments including oral nonpeptide GnRH antagonists and upstream regulators like kisspeptin for controlling the HPO axis.
- Extra-pituitary GnRH receptors exist in ovary, endometrium, and myometrium with direct effects
- New oral nonpeptide GnRH antagonists are being developed for clinical application
European Consensus Statement on congenital hypogonadotropic hypogonadism — pathogenesis, diagnosis and treatment
Boehm U, Bouloux PM, Dattani MT, et al.
Nature Reviews Endocrinology
Expert consensus on CHH, a disorder caused by deficient GnRH production, secretion, or action. Identified 25+ causal genes and established that pulsatile GnRH therapy can restore fertility. Noted that 10-20% of patients exhibit spontaneous recovery of reproductive function.
- Over 25 genes identified as causal for congenital hypogonadotropic hypogonadism
- Pulsatile GnRH therapy can induce fertility in most CHH patients